166809-69-4

Basic information

• Product Name: 1-(3-amino-propyl)-4-methyl-4-phenyl-piperidine
• Synonyms: 1-(3-amino-propyl)-4-methyl-4-phenyl-piperidine
• CAS NO: 166809-69-4
• Molecular Weight: 232.369
• Mol File: 166809-69-4.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 1-(3-amino-propyl)-4-methyl-4-phenyl-piperidine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(3-amino-propyl)-4-methyl-4-phenyl-piperidine(166809-69-4)
• EPA Substance Registry System: 1-(3-amino-propyl)-4-methyl-4-phenyl-piperidine(166809-69-4)

Safety Data

• Hazardous Substances Data: 166809-69-4(Hazardous Substances Data)

Upstream product

• 83948-53-2 3-bromopropylamine tert-butylcarbamate 
• 160132-91-2 4-methyl-4-phenyl piperidine 
• 160133-26-6 1-benzyl-4-methyl-4-phenyl piperidine 
• 3970-66-9 1-benzyl-4-methyl-piperidin-4-ol 
• 3612-20-2 1-phenylmethyl-4-piperidone 

Relevant articles and documents

SELECTIVE MELANIN CONCENTRATING HORMONE-1 (MCH1) RECEPTOR ANTAGONISTS AND USES THEREOF

This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of modifying feeding behavior of a subject which comprises administering to the subject an amount of a compound of the invention effective to decrease the consumption of food by the subject. This invention further provides a method of treating a feeding disorder in a subject which comprises administering to the subject an amount of a compound of the invention effective to decrease the consumption of food by the subject. In an embodiment of the invention, the feeding disorder is bulimia, bulimia nervosa or obesity.

Design and synthesis of novel α1a adrenoceptor-selective dihydropyridine antagonists for the treatment of benign prostatic hyperplasia

We report the synthesis and evaluation of novel ttia adrenoceptor subtype-selective antagonists. Systematic modification of the lipophilic 4,4-diphenylpiperidinyl moiety of the dihydropyridine derivatives 1 and 2 provided several highly selective and potent α1a antagonists. From this series, we identified the 4-(methoxycarbonyl)-4-phenylpiperidine analogue SNAP 5540 (-) [(-)-63] for further characterization. When examined in an isolated human prostate tissue assay, this compound was found to have a Ki of 2.8 nM, in agreement with the cloned human receptor binding data (Ki = 2.42 nM). Further evaluation of the compound in isolated dog prostate tissue showed a Ki of 3.6 nM and confirmed it to be a potent antagonist (Kb = 1.6 nM). In vivo, this compound effectively blocked the phenylephrine-stimulated increase in intraurethral pressure (IUP) in mongrel dogs, at doses which did not significantly affect the arterial pressure (diastolic blood pressure, DBF), with a DBF Kb/IUP-Kb ratio of 16. In addition, (-)-63 also showed greater than 40 000-fold selectivity over the rat L-type calcium channel and 200-fold selectivity over several G protein-coupled receptors, including histamine and serotonin subtypes. These findings prove that aia adrenoceptor-subtype selective antagonists such as (-)-63 may be developed as uroselective agents for an improved treatment of BPH over nonselective 0.1 antagonists such as prazosin and terazosin, with fewer side effects.